Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar
Three Phase I Biosimilar Trials Planned For 2023, Including Stelara And Humira Rivals
California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.
You may also be interested in...
In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.
Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.